News | 12 November 2021
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
The consideration for the acquisition is US $ 2.25 million
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The company has operations in North America, Asia, and Europe,
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
It is the world’s first DNA-based Covid vaccine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Biocon Biologics and Viatris co-developed the products
Subscribe To Our Newsletter & Stay Updated
